vendredi 29 mai 2020

Onco Actu du 29 mai 2020


2.13 ETIOLOGIE - NDMA



FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Extended-Release Products [FDA]











4.10 DÉP., DIAG. & PRONO. - POUMON



AI could predict risk of lung cancer coming back [Cancer Research UK]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Cancer drugs cause large cells that resist treatment; scientist aims to stop it [University of Texas]











Blocking tumor signals can hinder cancer’s spread [Penn Medicine]











5.12 IMMUNOTHÉRAPIES



Designer antibodies fight cancer by tethering immune cells to tumor cells [Science]










5.2.1 PHARMA - PARTENARIATS



Bristol Myers jumps into synthetic lethality with $65M Repare deal [Fierce Biotech]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer [NCI]











5.5.1 ASCO (GÉNÉRAL)



Sneak Peek at ASCO 2020 Plenary Sessions [OBR]










ASCO 2020 Late-Breakers Showcase Impact of COVID-19 on Cancer and More [OBR]











5.5.10 ASCO (HÉMATO)



Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML) [MD Anderson Cancer Center]











5.5.14 ASCO (VESSIE ET VOIES URINAIRES)



Immunotherapy Following Chemotherapy Offers Extended Survival to Patients with Advanced Urothelial Cancer [ASCO]











5.5.16 ASCO (MÉDECINE DE PRÉCISION)



Large Scale Precision Medicine Approach Successfully Applied to Pediatric Cancers With Poor Prognosis [ASCO]











5.5.18 ASCO (OBSERVATION)



Early Data Show Cancer Progression Associated With Increased Risk of Death in Patients With COVID-19 [ASCO]










Chemo Within 3 Months of COVID-19 Diagnosis Associated With an Increased Risk of Death in Patients With Thoracic Cancer [ASCO]











5.5.19 ASCO (REIN)



Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer [MD Anderson Cancer Center]











5.5.4 ASCO (IMMUNOTHÉRAPIES)



KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma [Merck]











5.5.4.7 ASCO (IMMUNOTHÉRAPIES- GASTRO-INTESTINAL)



ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients [Fierce Pharma]











Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer [Merck]











Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With Specific DNA Mutations [ASCO]











5.5.7 ASCO (GYNÉCO)



ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer [Fierce Pharma]











Immunotherapy Avelumab Shows Potential in Rare Gynecologic Cancer Resistant to Chemotherapy [ASCO]











5.5.8 ASCO (POUMON)



Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer [Roche]











5.5.8 ASCO (POUMON) - OSIMERTINIB



AstraZeneca bid to expand lung cancer drug's use boosted by trial data [Biopharma Dive]











ASCO: AstraZeneca's Tagrisso, headed for big sales boost, cuts lung cancer recurrence by 83% [Fierce Pharma]











AstraZeneca trumpets the good data they found for Tagrisso in an adjuvant setting for NSCLC — but many of the experts aren’t cheering along [EndPoints]










Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer [AstraZeneca]











Osimertinib After NSCLC Surgery Keeps Cancer at Bay for Patients With Key Mutation [AJMC]











Post-Surgery Osimertinib Delays Disease Recurrence in Patients With Localized Non-Small Cell Lung Cancer [ASCO]